Positions

Overview

  • Dr. Bennett received his A.B. from Howard College (Samford University) in 1954, and his M.D. (cum laude) from Harvard Medical School in Boston, Massachusetts in 1958. He served fellowships at the Massachusetts General Hospital (Rheumatology), the National Institutes of Health (Molecular biology) in Bethesda, Maryland and California Institute of Technology (Molecular Genetics) in Pasadena, California.He returned to Birmingham in 1965 to join the faculty at the University of Alabama at Birmingham (UAB). From 1970-82, he was Professor and Chair of the Department of Microbiology and Director of the Division of Clinical Immunology and Rheumatology. In 1982, he was named Professor and Chair of the Department of Medicine, and in 1992 was honored with the William and Evalina Spencer Chair in Medical Science Leadership. On October 1, 1993, he became the fourth President of the University of Alabama at Birmingham. In 1997, he was designated by the University Board of Trustees as Distinguished University Professor Emeritus and became President and Chief Operating Officer of BioCryst Pharmaceuticals, Inc. (1997-2008).

    Dr. Bennett has published over 200 scientific papers. He has been Editor, Cecil Textbook of Medicine, 19th, 20th, and 21st editions (1998-2000); Editor-in-Chief of Arthritis and Rheumatism (1975-1980); Editor-in-Chief of the American Journal of Medicine (1986-97).

    His contributions in research include the delineation of constant (C) and variable (V) regions of immunoglobulin molecules, based on peptide analyses of myeloma proteins. These studies resulted in a general hypothesis for the generation of antibody diversity. These studies also led to description of the phylogenetic development of the immune system and formed the basis for site attachment of complement in activation of the inflammatory pathway. His clinical research focused on the structures of rheumatoid factors and relationships to various infectious agents as initiators of the rheumatoid process.

    He has received awards from a number of distinguished organizations including the Seale Harris Award, Southern Medical Association (1987); Master, American College of Physicians (1990); Phillips Memorial Award, American College of Physicians (1993); Robert H. Williams Distinguished Chair of Medicine Award, Association of Professors of Medicine (1994); Francis Gilman Blake Award, Association of American Physicians (1997); Master, American College of Rheumatology (1998); Carol Nachman Medal, German Society of Rheumatology (2000); and the Kober Medal from the Association of American Physicians (2000). He has been awarded honorary degrees by the University of Alabama at Birmingham (D.Sc.1992), the University of Leipzig, Germany (Dr. Med [honoris causa] 1999), and the University of Zurich, Switzerland (Dr. Med [honoris causa] 2008).

    Dr. Bennett has been elected to membership in the American Academy of Microbiology, American Society for Clinical Investigation, the Association of American Physicians, the Institute of Medicine of the National Academy of Sciences, the American Academy of Arts and Sciences, and the Royal Society of Medicine, London, and an honorary member of the Ludwig Heilmeyer Society (Germany).

    His professional activities include President of the American College of Rheumatology (1981-1982); Chair, American Board of Internal Medicine (1994-1995); Chair, Board of Health Sciences Policy, Institute of Medicine, National Academy of Sciences (1988-1993); President, Association of Professors of Medicine (1991-1992); Chairman, Federated Council of Internal Medicine (1992-1993); NIH Director’s Panel on Clinical Research (1995-1998); President of the Association of American Physicians (1996-1997).

    Dr. Bennett has served on many scientific advisory boards, including the Scientific Advisory Committee for Massachusetts General Hospital (1983-1987; 2001-2005); Scientific Advisory Board Merck Sharp & Dohme Research Laboratories (1987-1989); Founding Board Deutsches RheumaForschungsZentrum, Berlin (1988-1998); Scientific Advisory Committee, Warren Alpert Foundation (1989-1997); Scientific Advisory Committee, Charles E. Culpepper Foundation, Inc. (1989-1995); Visiting Committee, Harvard Medical School (1992-1997); and Board of Governors of the Warren Grant Magnuson Clinical Center, at the National Institutes of Health (1996-1999).
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2019 CHOROIDEREMIA: Retinal Degeneration With an Unmet NeedRETINA.  39:2059-2069. 2019
    2019 Efficacy, Safety, and Durability of Voretigene Neparvovec-rzyl in RPE65 Mutation–Associated Inherited Retinal Dystrophy: Results of Phase 1 and 3 TrialsOphthalmology: Journal of The American Academy of Ophthalmology.  126:1273-1285. 2019
    2019 AKT3 Gene Transfer Promotes Anabolic Reprogramming and Photoreceptor Neuroprotection in a Pre-clinical Model of Retinitis PigmentosaMolecular Therapy.  27:1313-1326. 2019
    2019 CRISPR Activation Enhances In Vitro Potency of AAV Vectors Driven by Tissue-Specific PromotersMolecular Therapy - Methods and Clinical Development.  13:380-389. 2019
    2019 Identification of a novel pathogenic missense mutation in PRPF31 using whole exome sequencing: A case reportNature Reviews Neurology.  103:761-767. 2019
    2019 Detailed retinal phenotype of Boucher-Neuhäuser syndrome associated with mutations in PNPLA6 mimicking choroideremiaOphthalmic Genetics.  40:267-275. 2019
    2019 Blinded by the light: A nonhuman primate model of achromatopsiaJournal of Clinical Investigation.  129:513-515. 2019
    2019 Comparative AAV-EGFP transgene expression using vector serotypes 1–9, 7M8, and 8b in human pluripotent stem cells, RPEs, and human and rat cortical neuronsStem Cells International.  2019. 2019
    2019 Depicting brighter possibilities for treating blindnessScience Translational Medicine.  11. 2019
    2019 RNA Splicing Factor Mutations That Cause Retinitis Pigmentosa Result in Circadian DysregulationJournal of Biological Rhythms2019
    2019 Utility of in Vitro Mutagenesis of RPE65 Protein for Verification of Mutational Pathogenicity before Gene TherapyJAMA Ophthalmology2019
    2018 Prescreening whole exome sequencing results from patients with retinal degeneration for variants in genes associated with retinal degenerationASIA CCS 2013 - Proceedings of the 8th ACM SIGSAC Symposium on Information, Computer and Communications Security.  12:49-63. 2018
    2018 Erratum to: An Autogenously Regulated Expression System for Gene Therapeutic Ocular Applications (Scientific Reports, (2015), 5, 1, (17105), 10.1038/srep17105)Scientific Reports.  8. 2018
    2018 RDH12 mutations cause a severe retinal degeneration with relatively spared rod functionInvestigative Ophthalmology & Visual Science.  59:5225-5236. 2018
    2018 Spliceosome-Mediated Pre-mRNA trans-Splicing Can Repair CEP290 mRNAMolecular Therapy : Nucleic Acids.  12:294-308. 2018
    2018 Voretigene neparvovec-rzyl for the treatment of biallelic RPE65 mutation–associated retinal dystrophyExpert Opinion on Orphan Drugs.  6:457-464. 2018
    2018 Comparing clinical perimetry and population receptive field measures in patients with choroideremiaInvestigative Ophthalmology & Visual Science.  59:3249-3258. 2018
    2018 Amelioration of Neurosensory Structure and Function in Animal and Cellular Models of a Congenital BlindnessMolecular Therapy.  26:1581-1593. 2018
    2018 Novel mobility test to assess functional vision in patients with inherited retinal dystrophiesThoracic Surgery Clinics.  46:247-259. 2018
    2018 SIRT1 and NRF2 gene transfer mediate distinct neuroprotective effects upon retinal ganglion cell survival and function in experimental optic neuritisInvestigative Ophthalmology & Visual Science.  59:1212-1220. 2018
    2018 Use of induced pluripotent stem cell models to probe the pathogenesis of Choroideremia and to develop a potential treatmentStem Cell Research.  27:140-150. 2018
    2018 On variants and disease-causing mutations: Case studies of a SEMA4A variant identified in inherited blindnessOphthalmic Genetics.  39:144-146. 2018
    2018 Evidence for Amino Acid Sequence Differences among Proteins resembling the L-Chain Subunits of ImmunoglobulinsJournal of Immunology.  200:27-37. 2018
    2017 Evaluating efficiencies of dual AAV approaches for retinal targetingFrontiers in Neuroscience.  11. 2017
    2017 Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trialLancet.  390:849-860. 2017
    2017 The Role of the Human Visual Cortex in Assessment of the Long-Term Durability of Retinal Gene Therapy in Follow-on RPE65 Clinical Trial PatientsOphthalmology: Journal of The American Academy of Ophthalmology.  124:873-883. 2017
    2017 Taking Stock of Retinal Gene Therapy: Looking Back and Moving ForwardMolecular Therapy.  25:1076-1094. 2017
    2017 Protocols for visually guided navigation assessment of efficacy of retina-directed cell or gene therapy in caninesFrontiers in Neuroscience.  11. 2017
    2017 Isolated maculopathy associated with biallelic CRB1 mutationsOphthalmic Genetics.  38:190-193. 2017
    2017 Evaluation of Dose and Safety of AAV7m8 and AAV8BP2 in the Non-Human Primate RetinaHuman Gene Therapy.  28:154-167. 2017
    2016 Institutional conflict of interestJAMA Ophthalmology.  134:1334-1335. 2016
    2016 Gene Therapy and Stem Cell Transplantation in Retinal Disease: The New FrontierOphthalmology: Journal of The American Academy of Ophthalmology.  123:S98-S106. 2016
    2016 Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trialLancet.  388:661-672. 2016
    2016 In vitro and in vivo rescue of aberrant splicing in CEP290-associated LCA by antisense oligonucleotide deliveryHuman Molecular Genetics.  25:2552-2563. 2016
    2016 Retinas in a Dish Peek into Inherited Retinal DegenerationInternational Journal of Pharmaceutical and Healthcare Marketing.  18:688-689. 2016
    2016 The Thioredoxin Encoded by the Rod-Derived Cone Viability Factor Gene Protects Cone Photoreceptors Against Oxidative StressActa Chimica Slovenica.  24:909-923. 2016
    2016 Corrigendum to “Efficient gene delivery to photoreceptors using AAV2/rh10 and rescue of the Rho–/– mouse” (Molecular Therapy - Methods and Clinical Development (2015) 2 (S2329050116300286) (10.1038/mtm.2015.16))Molecular Therapy - Methods and Clinical Development.  3:16032. 2016
    2015 An Autogenously Regulated Expression System for Gene Therapeutic Ocular ApplicationsScientific Reports.  5. 2015
    2015 Plasticity of the human visual system after retinal gene therapy in patients with Leber's congenital amaurosisScience Translational Medicine.  7. 2015
    2015 Erratum: AAV-Mediated Gene Therapy for Choroideremia: Preclinical Studies in Personalized Models (PLOS ONE (2015) 10:6 (e0129982) (doi:10.1371/journal.pone.0129982))PLoS ONE.  10. 2015
    2015 Basal exon skipping and genetic pleiotropy: A predictive model of disease pathogenesisScience Translational Medicine.  7. 2015
    2015 Efficient gene delivery to photoreceptors using AAV2/rh10 and rescue of the Rho−/− mouseMolecular Therapy - Methods and Clinical Development.  2:15016. 2015
    2015 Exploiting metabolic and antioxidant pathways to maintain vision in blinding diseaseJournal of Clinical Investigation.  125:1390-1392. 2015
    2015 Neuromyelitis optica and multiple sclerosis: Seeing differences through optical coherence tomographyMultiple Sclerosis.  21:678-688. 2015
    2015 The status of RPE65 gene therapy trials: Safety and efficacyJournal of Epidemiology.  5. 2015
    2015 Thioredoxin rod-derived cone viability factor protects against photooxidative retinal damageFree Radical Biology and Medicine.  81:22-29. 2015
    2014 My career path for developing gene therapy for blinding diseases: The importance of mentors, collaborators, and opportunitiesHuman Gene Therapy.  25:663-670. 2014
    2014 Promising first steps in gene therapy for choroideremiaHuman Gene Therapy.  25:96-97. 2014
    2014 fMRI of retina-originated phosphenes experienced by patients with leber congenital amaurosisPLoS ONE.  9. 2014
    2014 Adeno-associated virus 8-mediated gene therapy for choroideremia: Preclinical studies in in vitro and in vivo modelsJournal of Gene Medicine.  16:122-130. 2014
    2014 CEP290 and the primary ciliumTransplantation.  801:519-525. 2014
    2014 Differential targeting of feline photoreceptors by recombinant adeno-associated viral vectors: Implications for preclinical gene therapy trialsGene Therapy.  21:913-920. 2014
    2014 Efficient transduction and optogenetic stimulation of retinal bipolar cells by a synthetic adeno-associated virus capsid and promoterBiomedical Engineering..  6:1175-1190. 2014
    2014 High-resolution adaptive optics retinal imaging of cellular structure in choroideremiaInvestigative Ophthalmology & Visual Science.  55:6381-6397. 2014
    2014 Novel mathematical algorithm for pupillometric data analysisPhysical and Occupational Therapy in Pediatrics.  113:221-225. 2014
    2014 Screening of a Large Cohort of Leber Congenital Amaurosis and Retinitis Pigmentosa Patients Identifies Novel LCA5 Mutations and New Genotype-Phenotype Correlations. [34, 11, 1537-1546, 10.1002/humu.22398]Human Mutation.  35:150-150. 2014
    2014 The Pex1-G844D mouse: A model for mild human Zellweger spectrum disorderMolecular Genetics and Metabolism.  111:522-532. 2014
    2013 Disruption of CEP290 microtubule/membrane-binding domains causes retinal degenerationJournal of Clinical Investigation.  123:4525-4539. 2013
    2013 Immunology of AAV-mediated gene transfer in the eyeFrontiers in Immunology.  4. 2013
    2013 Stem cells set their sights on retinitis pigmentosa: Skin cells from a patient with a form of inherited blindness have been reprogrammed into retinal cells and successfully transplanted into miceOverview.  2013. 2013
    2013 Erratum: Progress in gene therapy for neurological disorders (Nature Reviews Neurology (2013) 9 (277-291) DOI: 10.1038/nrneurol.2013.56)Nature Reviews Neurology.  9:298. 2013
    2013 Three-year follow-up after unilateral subretinal delivery of adeno-associated virus in patients with leber congenital amaurosis type 2Ophthalmology: Journal of The American Academy of Ophthalmology.  120:1283-1291. 2013
    2013 AAV-Mediated Gene Therapy for Choroideremia: Preclinical Studies in Personalized ModelsPLoS ONE.  8. 2013
    2013 Seeing the lightScience Translational Medicine.  5. 2013
    2013 AAV9 Targets Cone Photoreceptors in the Nonhuman Primate RetinaPLoS ONE.  8. 2013
    2013 Progress in gene therapy for neurological disordersNature Reviews Neurology.  9:277-291. 2013
    2013 Screening of a large cohort of leber congenital amaurosis and retinitis pigmentosa patients identifies novel lca5 mutations and new genotype-phenotype correlationsHuman Mutation.  34:1537-1546. 2013
    2012 Mutations in RPGR and RP2 account for 15% of males with simplex retinal degenerative diseaseInvestigative Ophthalmology & Visual Science.  53:8232-8237. 2012
    2012 The Bionic Retina: A Small Molecule with Big Potential for Visual RestorationNeuron.  75:185-187. 2012
    2012 Pupillometric analysis for assessment of gene therapy in Leber Congenital Amaurosis patientsCancer Informatics.  11. 2012
    2012 The signalling role of the αvβ5-integrin can impact the efficacy of AAV in retinal gene therapyPharmaceuticals.  5:447-459. 2012
    2012 Nxnl2 splicing results in dual functions in neuronal cell survival and maintenance of cell integrityHuman Molecular Genetics.  21:2298-2311. 2012
    2012 Gene therapy: AAV2 gene therapy readministration in three adults with congenital blindnessScience Translational Medicine.  4. 2012
    2012 Antisense oligonucleotide (AON)-based therapy for leber congenital amaurosis caused by a frequent mutation in CEP290Molecular Therapy : Nucleic Acids.  1:e14. 2012
    2011 Adeno-associated virus mediated gene therapy for retinal degenerative diseasesMethods in Molecular Biology.  807:179-218. 2011
    2011 Dosage thresholds for AAV2 and AAV8 photoreceptor gene therapy in monkeyScience Translational Medicine.  3. 2011
    2011 The evolution of retinal gene therapy: From DNA to FDARetina Today.  55-58. 2011
    2011 Switching on the lights: The use of optogenetics to advance retinal gene therapyMolecular Therapy.  19:1190-1192. 2011
    2011 Dosage thresholds for AAV2 and AAV8 photoreceptor gene therapy in monkeyScience Translational Medicine.  3. 2011
    2011 Disruption of intraflagellar protein transport in photoreceptor cilia causes Leber congenital amaurosis in humans and miceJournal of Clinical Investigation.  121:2169-2180. 2011
    2011 The human visual cortex responds to gene therapy-mediated recovery of retinal functionJournal of Clinical Investigation.  121:2160-2168. 2011
    2011 Gene therapy in ophthalmology: Validation on cultured retinal cells and explants from postmortem human eyesHuman Gene Therapy.  22:587-593. 2011
    2011 Erratum: Lighting a candle in the dark: Advances in genetics and gene therapy of recessive retinal dystrophies (Journal of Clinical Investigation (2010) 120, 9 (3042-3053) DOI: 10.1172/JCI42258)Journal of Clinical Investigation.  121:456. 2011
    2011 Erratum: The human visual cortex responds to gene therapy-mediated recovery of retinal function (The Journal of Clinical Investigation (2011) 121, 6, (2160-2168) DOI: 10.1172/JCI57377)Journal of Clinical Investigation.  121:2945. 2011
    2011 Suppression and replacement gene therapy for autosomal dominant disease in a murine model of dominant retinitis pigmentosaMolecular Therapy.  19:642-649. 2011
    2010 Lighting a candle in the dark: Advances in genetics and gene therapy of recessive retinal dystrophiesJournal of Clinical Investigation.  120:3042-3053. 2010
    2010 Safety and efficacy of subretinal readministration of a viral vector in large animals to treat congenital blindnessScience Translational Medicine.  2. 2010
    2010 Gene therapy for leber's congenital amaurosis is safe and effective through 1.5 years after vector administrationMolecular Therapy.  18:643-650. 2010
    2009 Gene therapy for color blindnessNew England Journal of Medicine.  361:2483. 2009
    2009 Using the NAFX to measure the effectiveness over time of gene therapy in canine LCAInvestigative Ophthalmology & Visual Science.  50:4685-4692. 2009
    2009 Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trialLancet.  374:1597-1605. 2009
    2009 Tie2Cre-mediated inactivation of plexinD1 results in congenital heart, vascular and skeletal defectsAging Today.  325:82-93. 2009
    2008 Safety and efficacy of gene transfer for Leber's congenital amaurosisNew England Journal of Medicine.  358:2240-2248. 2008
    2008 Serotype-dependent packaging of large genes in adeno-associated viral vectors results in effective gene delivery in miceJournal of Clinical Investigation.  118:1955-1964. 2008
    2008 Novel AAV serotypes for improved ocular gene transferJournal of Gene Medicine.  10:375-382. 2008
    2008 Reversal of blindness in animal models of leber congenital amaurosis using optimized AAV2-mediated gene transferMolecular Therapy.  16:458-465. 2008
    2007 Accelerated mortality from hydrocephalus and pneumonia in mice with a combined deficiency of SPAG6 and SPAG16L reveals a functional interrelationship between the two central apparatus proteinsJournal of Patient Experience.  64:360-376. 2007
    2007 Retinal progenitor cells - Timing is everythingNew England Journal of Medicine.  356:1577-1579. 2007
    2007 Gene transfer to ocular stem cells by early gestational intraamniotic injection of lentiviral vectorMolecular Therapy.  15:579-587. 2007
    2006 Retinal ganglion cell loss induced by acute optic neuritis in a relapsing model of multiple sclerosisMultiple Sclerosis.  12:526-532. 2006
    2006 In Vivo Delivery of Recombinant Viruses to the Fetal Murine Cochlea: Transduction Characteristics and Long-Term Effects on Auditory FunctionMolecular Therapy.  14:328-335. 2006
    2006 Eye movement recordings as an effectiveness indicator of gene therapy in RPE65-deficient canines: Implications for the ocular motor systemInvestigative Ophthalmology & Visual Science.  47:2865-2875. 2006
    2006 Safety of Recombinant Adeno-Associated Virus Type 2-RPE65 Vector Delivered by Ocular Subretinal InjectionMolecular Therapy.  13:1074-1084. 2006
    2006 Deficiency of SPAG16L causes male infertility associated with impaired sperm motilityJournal of Computational and Applied Mathematics.  74:751-759. 2006
    2006 An aye for eye gene therapyHuman Gene Therapy.  17:177-179. 2006
    2005 The distribution, concentration, and toxicity of enhanced green fluorescent protein in retinal cells after genomic or somatic (virus-mediated) gene transferMolecular Vision.  11:1236-1245. 2005
    2005 Spatial and temporal expression patterns of the choroideremia gene in the mouse retinaMolecular Vision.  11:1052-1060. 2005
    2005 ABCA4-associated retinal degenerations spare structure and function of the human parapapillary retinaInvestigative Ophthalmology & Visual Science.  46:4739-4746. 2005
    2005 Long-term restoration of rod and cone vision by single dose rAAV-mediated gene transfer to the retina in a canine model of childhood blindnessMolecular Therapy.  12:1072-1082. 2005
    2005 Herpes simplex virus type 1 glycoprotein E is required for axonal localization of capsid, tegument, and membrane glycoproteinsJournal of Virology.  79:13362-13372. 2005
    2005 Oxygen distribution and vascular injury in the mouse eye measured by phosphorescence-lifetime imagingAnatomischer Anzeiger.  44:5239-5248. 2005
    2005 Dissecting the axoneme interactome: The mammalian orthologue of chlamydomonas PF6 interacts with sperm-associated antigen 6, the mammalian orthologue of Chlamydomonas PF16Molecular and Cellular Proteomics.  4:914-923. 2005
    2005 Persistent fetal ocular vasculature in mice deficient in Bax and BakHuman Pathology.  123:797-802. 2005
    2005 Identifying photoreceptors in blind eyes caused by RPE65 mutations: Prerequisite for human gene therapy successProceedings of the National Academy of Sciences.  102:6177-6182. 2005
    2005 Nonhuman primate models for diabetic ocular neovascularization using AAV2-mediated overexpression of vascular endothelial growth factorGynecologic Investigation.  54:1141-1149. 2005
    2005 Disease expression in Usher syndrome caused by VLGR1 gene mutation (USH2C) and comparison with USH2A phenotypeInvestigative Ophthalmology & Visual Science.  46:734-743. 2005
    2005 Long-term inducible gene expression in the eye via adeno-associated virus gene transfer in nonhuman primatesHuman Gene Therapy.  16:178-186. 2005
    2004 Systemic rapamycin inhibits retinal and choroidal neovascularization in miceMolecular Vision.  10:964-972. 2004
    2004 Adeno-associated viruses containing bFGF or BDNF are neuroprotective against excitotoxicitySouthern Online Journal of Nursing Research (SOJNR).  29:379-386. 2004
    2004 Effect of over-expression of pigment epithelium derived factor (PEDF) on developing retinal vasculature in the mouseMolecular Vision.  10:837-844. 2004
    2004 Systemic but not intraocular Epo gene transfer protects the retina from light-and genetic-induced degenerationMolecular Therapy.  10:855-861. 2004
    2004 Adenovirus-mediated delivery of catalase to retinal pigment epithelial cells protects neighboring photoreceptors from photo-oxidative stressHuman Gene Therapy.  15:960-967. 2004
    2004 Light damage induced changes in mouse retinal gene expressionExperimental Eye Research.  79:239-247. 2004
    2004 Impairment of the transient pupillary light reflex in Rpe65-/- mice and humans with leber congenital amaurosisInvestigative Ophthalmology & Visual Science.  45:1259-1271. 2004
    2004 Mutations in ABCA4 result in accumulation of lipofuscin before slowing of the retinoid cycle: A reappraisal of the human disease sequenceHuman Molecular Genetics.  13:525-534. 2004
    2004 In utero gene therapy rescues vision in a murine model of congenital blindnessMolecular Therapy.  9:182-188. 2004
    2003 Increased expression of ceruloplasmin in the retina following photic injuryMolecular Vision.  9:151-158. 2003
    2003 Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in mouse modelMolecular Vision.  9:210-216. 2003
    2003 Proapoptotic Bcl-2 family members, Bax and Bak, are essential for developmental photoreceptor apoptosisInvestigative Ophthalmology & Visual Science.  44:3598-3605. 2003
    2003 Delivery of adeno-associated virus vectors to the fetal retina: Impact of viral capsid proteins on retinal neuronal progenitor transductionJournal of Virology.  77:7957-7963. 2003
    2003 Immune response following intraocular delivery of recombinant viral vectorsGene Therapy.  10:977-982. 2003
    2003 Adeno-associated virus encoding green fluorescent protein as a label for retinal pigment epitheliumInvestigative Ophthalmology & Visual Science.  44:772-780. 2003
    2003 Efficient trans-splicing in the retina expands the utility of adeno-associated virus as a vector for gene therapyHuman Gene Therapy.  14:37-44. 2003
    2003 Gene therapy and animal models for retinal disease.The Journal of frailty & aging.  37:188-198. 2003
    2003 Gene therapy for Leber congenital amaurosisNovartis Foundation symposium.  255:195-202. 2003
    2003 Gene therapy for ocular neovascularization: A cure in sightMycologist.  13:317-322. 2003
    2002 Pigment epithelium-derived factor expression in the developing mouse eyeMolecular Vision.  8:449-454. 2002
    2002 Lateral connectivity and contextual interactions in macaque primary visual cortexNeuron.  36:739-750. 2002
    2002 Phenotypic rescue after adeno-associated virus-mediated delivery of 4-sulfatase to the retinal pigment epithelium of feline mucopolysaccharidosis VIJournal of Gene Medicine.  4:613-621. 2002
    2002 Inhibition of retinal neovascularization by intraocular viral-mediated delivery of anti-angiogenic agentsMolecular Therapy.  6:490-494. 2002
    2002 Pharmacological regulation of protein expression from adeno-associated viral vectors in the eyeMolecular Therapy.  6:238-242. 2002
    2002 A deviant immune response to viral proteins and transgene product is generated on subretinal administration of adenovirus and adeno-associated virusMolecular Therapy.  5:125-132. 2002
    2002 Macular pigment and lutein supplementation in choroideremiaExperimental Eye Research.  74:371-381. 2002
    2002 Novel mutation in the TIMP3 gene causes Sorsby fundus dystrophyHuman Pathology.  120:376-379. 2002
    2001 Exchange of surface proteins impacts on viral vector cellular specificity and transduction characteristics: The retina as a modelHuman Molecular Genetics.  10:3075-3081. 2001
    2001 Localization of pigment epithelium derived factor (PEDF) in developing and adult human ocular tissuesMolecular Vision.  7:154-163. 2001
    2001 Gene therapy and retinitis pigmentosa: Advances and future challengesVirginia medical monthly.  23:662-668. 2001
    2001 Strain-dependent anterior segment neovascularization following intravitreal gene transfer of basic fibroblast growth factor (bFGF)Journal of Gene Medicine.  3:252-259. 2001
    2001 Melatonin delays photoreceptor degeneration in the rds/rds mouseNeuroReport.  12:1011-1014. 2001
    2001 Pharmacologically regulated gene expression in the retina following transduction with viral vectorsGene Therapy.  8:442-446. 2001
    2001 AAV-mediated delivery of ciliary neurotrophic factor prolongs photoreceptor survival in the rhodopsin knockout mouseMolecular Therapy.  3:241-248. 2001
    2001 Gene therapy restores vision in a canine model of childhood blindnessNature Genetics.  28:92-95. 2001
    2001 Long-term protection of retinal structure but not function using rAAV.CNTF in animal models of retinitis pigmentosaMolecular Therapy.  4:461-472. 2001
    2000 Gene therapy for retinitis pigmentosaPacific Symposium on Biocomputing. Pacific Symposium on Biocomputing.  2:420-425. 2000
    2000 Disease expression of RP1 mutations causing autosomal dominant retinitis pigmentosaInvestigative Ophthalmology & Visual Science.  41:1898-1908. 2000
    2000 Additional transduction events after subretinal readministration of recombinant adeno-associated virusHuman Gene Therapy.  11:449-457. 2000
    2000 Mutation of a nuclear receptor gene, NR2E3, causes enhanced S cone syndrome, a disorder of retinal cell fateNature Genetics.  24:127-131. 2000
    2000 Application of adenoviral vectors. Analysis of eye development.Methods in Molecular Biology.  135:525-535. 2000
    2000 Gene therapy for ocular diseaseMolecular Therapy.  1:501-505. 2000
    1999 Basic fibroblast growth factor induces a transformed phenotype in normal human melanocytesOncogene.  18:6469-6476. 1999
    1999 Infection with adeno-associated virus may protect against excitotoxicityNeuroReport.  10:2887-2890. 1999
    1999 Stable transgene expression in rod photoreceptors after recombinant adeno-associated virus-mediated gene transfer to monkey retinaProceedings of the National Academy of Sciences.  96:9920-9925. 1999
    1999 Persistent transgene product in retina, optic nerve and brain after intraocular injection of rAAVVision Research.  39:2545-2553. 1999
    1999 bcl-2 gene therapy exacerbates excitotoxicityHuman Gene Therapy.  10:1715-1720. 1999
    1998 Temporal and spatial regulation of gene expression mediated by the promoter for the human tissue inhibitor of metalloproteinases-3 (TIMP-3)- encoding geneArchives of orthopaedic and traumatic surgery. Archiv fur orthopadische und Unfall-Chirurgie.  211:228-237. 1998
    1998 Adenovirus-mediated delivery of rhodopsin-promoted bcl-2 results in a delay in photoreceptor cell death in the rd/rd mouseGene Therapy.  5:1156-1164. 1998
    1997 Adenovirus mediated genetic therapy for hereditary retinal degenerationInvestigative Ophthalmology & Visual Science.  38. 1997
    1997 Adenovirus-mediated delivery of bcl-2 in conjunction with pde prolongs the delay in photoreceptor cell death in the rd/rd mouseInvestigative Ophthalmology & Visual Science.  38. 1997
    1997 Development of cataracts in a line of mice transgenic for human rhodopsin-promoted LacZInvestigative Ophthalmology & Visual Science.  38. 1997
    1997 Real-time, noninvasive in vivo assessment of adeno-associated virus- mediated retinal transductionInvestigative Ophthalmology & Visual Science.  38:2857-2863. 1997
    1997 Cell-mediated immune response and stability of intraocular transgene expression after adenovirus-mediated deliveryInvestigative Ophthalmology & Visual Science.  38:2224-2233. 1997
    1997 A carboxy-terminal truncation of 99 amino acids resulting from a novel mutation (Arg555-->stop) in the CHM gene leads to choroideremia.Experimental Eye Research.  64:487-490. 1997
    1997 Spectrum of mutations in the RPGR gene that are identified in 20% of families with X-linked retinitis pigmentosaJournal of Cybersecurity Education, Research, and Practice.  61:1287-1292. 1997
    1996 Humoral response after administration of E1-deleted adenoviruses: Immune privilege of the subretinal spaceHuman Gene Therapy.  7:1763-1769. 1996
    1996 Photoreceptor cell rescue in retinal degeneration (rd) mice by in vivo gene therapyNature Medicine.  2:649-654. 1996
    1996 Humoral response after administration of E1-deleted adenoviruses: Immune privilege of the subretinal spaceInvestigative Ophthalmology & Visual Science.  37. 1996
    1996 Preferential rod and cone photoreceptor abnormalities in heterozygotes with point mutations in the RDS gene.Experimental Eye Research.  63:603-608. 1996
    1995 Sequence analysis of the 5.34-kb 5′ flanking region of the human rhodopsin-encoding geneGene.  167:317-320. 1995
    1995 In vivo gene transfer into murine corneal endothelial and trabecular meshwork cellsInvestigative Ophthalmology & Visual Science.  36:2211-2215. 1995
    1994 Adenovirus vector-mediated in vivo gene transfer into adult murine retinaInvestigative Ophthalmology & Visual Science.  35:2535-2542. 1994
    1994 Training the future internal medicine subspecialistElectronic Journal of Biotechnology.  96:559-561. 1994
    1993 The Affliction of Internal MedicineNew England Journal of Medicine.  329:212. 1993
    1993 Generating more generalists: An agenda of renewal for internal medicineThrombosis.  119:1125-1129. 1993
    1993 Interactions of cell-surface galactosyltransferase with immunoglobulinsMolecular Immunology.  30:265-275. 1993
    1993 Interactions of galactosyltransferase with serum and secretory immunoglobulins and their component chainsMolecular Immunology.  30:277-286. 1993
    1993 Medical informatics and the need for general internists [6]Thrombosis.  118:750-751. 1993
    1993 United we standThrombosis.  118:903-904. 1993
    1992 A locus control region adjacent to the human red and green visual pigment genesNeuron.  9:429-440. 1992
    1992 Activism in academic internal medicineThrombosis.  117:259-260. 1992
    1992 Development of a didactic curriculum in science related to internal medicineThrombosis.  116:1088-1090. 1992
    1992 General internal medicine and general internists: Recognizing a national needThrombosis.  117:778-779. 1992
    1991 Unusual topography of bovine rhodopsin promoter-IacZ fusion gene expression in transgenic mouse retinasNeuron.  6:187-199. 1991
    1989 Analysis of the spectrin binding domains of globinJournal of Healthcare Leadership.  164:894-902. 1989
    1988 Conversion of the Beckman liquid phase sequencer to a gas-liquid phase sequencerHeart Rhythm.  175:39-51. 1988
    1987 Heterogeneity of binding of monoclonal IgA to staphylococcal protein A is related to the IgA polymerization stateImmunology Letters.  16:11-14. 1987
    1987 Interactions between surface molecules and the cytoskeleton in the lymphocyte.Transactions- American Clinical and Climatological Association.  99:119-125. 1987
    1987 The infectious etiology of chronic rheumatic diseasesSeminars in Arthritis and Rheumatism.  17:1-23. 1987
    1986 Biochemical characterization of Fcγ receptors of mouse DCH-5 cell lineImmunobiology.  172:81-91. 1986
    1986 Interleukin 1-like factor produced by a hybrid of an adherent mouse spleen cell and a thymoma cellImmunology Letters.  13:143-149. 1986
    1986 Purification of spfctrin and its subunits by high-performance liquid chromatographyHematological Oncology.  369:159-164. 1986
    1986 Simple device for high-performance liquid chromatographic separation on microbore columnsHematological Oncology.  370:508-512. 1986
    1986 The stoichiometry of J chain in human secretory dimeric IgAMolecular Immunology.  23:541-544. 1986
    1985 Secondary structure of the immunoglobulin J chain. (circular dichroism/hydrophobicity profile/tertiary structure/antiparallel β-barrel)Proceedings of the National Academy of Sciences.  82:5905-5909. 1985
    1985 A modified system for thiazolinone conversion to thiohydantoin derivatives and their separation by high-pressure liquid chromatographyHeart Rhythm.  150:457-462. 1985
    1985 Isolation, characterization, and amino-terminal amino acid sequence analysis of human neutrophil elastase from normal donorsHeart Rhythm.  149:153-162. 1985
    1984 Use of mini-octadecylsilane ultrasphere column in high-pressure liquid chromatography for protein structural studiesHeart Rhythm.  137:256-260. 1984
    1984 Amino Acid Sequence of Human D of the Alternative Complement PathwayBiomarker Insights.  23:2482-2486. 1984
    1984 Identification of phenylthiohydantoin derivatives of substituted amino acids encountered during amono acid sequence analysis by high-performance liquid chromatographyHematological Oncology.  314:467-470. 1984
    1984 Partial characterisation of the high and low molecular weight forms of P388D1‐derived interleukin 1Journal of Cellular Biochemistry.  26:65-73. 1984
    1983 Amino-terminal amino acid sequence of p10, the fifth major gag polypeptide of avian sarcoma and leukemia virusesJournal of Virology.  45:885-888. 1983
    1983 A comparison of fluorescamine and o-phthaldialdehyde as effective blocking reagents in protein sequence analyses by the Beckman sequencerHeart Rhythm.  131:337-340. 1983
    1983 American rheumatology: markingsCancer Genetics and Cytogenetics.  26:548-552. 1983
    1983 Exclusive Use of High Pressure Liquid Chromatography for The Determination of the Complete Amino Acid Sequence of The 12K Fragment of Avian Sarcoma Virus Structural Protein p27Journal of liquid chromatography.  6:249-258. 1983
    1982 Selective dansylation of M protein within intact influenza virionsJournal of Virology.  44:871-876. 1982
    1982 Buffer electrofocusing of Interleukin ISociology of Sport Journal.  2:241-246. 1982
    1982 The H-2kk antigen: Isolation using monoclonal immunoadsorbent chromatography and sequence analysis without radioisotopesMolecular Immunology.  19:1-11. 1982
    1981 Interleukin 1: Production by P388D1 cells attached to microcarrier beadsJournal of Immunological Methods.  46:197-204. 1981
    1981 Purification and characterization of the gag gene products of avian-type C retroviruses by high-pressure liquid chromatographyHeart Rhythm.  112:128-134. 1981
    1981 Use of fluorescamine as an effective blocking reagent to reduce the background in protein sequence analyses by the beckman automated sequencerHeart Rhythm.  112:158-162. 1981
    1981 An improved procedure for high-sensitivity microsequencing: Use of aminoethyl aminopropyl glass beads in the beckman sequencer and the Ultrasphere ODS column for PTH amino acid identificationHeart Rhythm.  110:355-359. 1981
    1981 Reverse phase ion pair high performance liquid chromatography of viral tryptic glycopeptidesJournal of liquid chromatography.  4:587-598. 1981
    1980 Monoclonal and allospecific H-2K(k) antisera precipitate a high molecular weight proteinJournal of Immunology.  125:2295-2298. 1980
    1980 Alignment of the peptides derived from acid-catalyzed cleavage of an aspartylprolyl bond in the major internal structural polypeptide of avian retrovirusesJournal of Biological Chemistry.  255:6962-6965. 1980
    1980 A simple modification on the vacuum system of the Beckman automated sequencer to improve the efficiency of edman degradationHeart Rhythm.  102:35-38. 1980
    1980 Partial amino acid sequence of human factor D:homology with serine proteases.Proceedings of the National Academy of Sciences.  77:1116-1119. 1980
    1980 Separation of influenza hemagglutinin tryptic glycopeptides by ion-pair reverse-phase high-performance liquid chromatography (HPLC)Journal of Biochemical and Biophysical Methods.  3:61-63. 1980
    1979 Reverse phase ion‐pair chromatography of viral glycopeptidesHrc -Heidelberg-.  2:149-150. 1979
    1979 Structure of the membrane protein of influenza virus. I. Isolation and characterization of cyanogen bromide cleavage productsJournal of Virology.  30:759-766. 1979
    1978 The molecular structure and interrelationships of murine T lymphoid cell-surface antigens.Applied Psychological Measurement.  7:283-317. 1978
    1978 Computer-Assisted high-pressure liquid chromatography of radio-labelled phenylthiohydantoin amino acidsHematological Oncology.  156:35-41. 1978
    1978 Methanol solvent system for rapid analysis of phenylthiohydantoin amino acids by high-pressure liquid chromatographyHematological Oncology.  148:532-535. 1978
    1978 Amino-terminal amino acid sequence of the major structural polypeptides of avian retroviruses: Sequence homology between reticuloendotheliosis virus p30 and p30s of mammalian retrovirusesProceedings of the National Academy of Sciences.  75:2708-2712. 1978
    1978 Quantitative yields of underivatized peptides by HPLCHrc -Heidelberg-.  1:177-178. 1978
    1978 The infectious etiology of rheumatoid arthritis.Cancer Genetics and Cytogenetics.  21:531-538. 1978
    1977 Primary Structure of Human J Chain: Alignment of Peptides from Chemical and Enzymic HydrolysesBiomarker Insights.  16:3507-3513. 1977
    1977 Primary Structure of Human J Chain: Isolation and Characterization of Tryptic and Chymotryptic Peptides of Human J ChainBiomarker Insights.  16:3501-3507. 1977
    1977 A Preliminary Study Using Electron Capture Detection of Pentafluorophenylthiohydantoin Amino Acid DerivativesProceedings of the Society for Experimental Biology and Medicine.  155:287-289. 1977
    1977 Structural analysis of the peptides derived from specific acid catalyzed hydrolysis at aspartylprolyl peptide bonds in human J chainJournal of Immunology.  118:67-70. 1977
    1976 Sequence analysis of human J chain. Amino terminal location of a disulfide bond linking the immunoglobulin heavy chainJournal of Healthcare Leadership.  73:92-97. 1976
    1976 A comparative analysis of the C1 binding ability of fragments derived from complement fixing and non complement fixing IgM proteinsJournal of Clinical Investigation.  58:16-21. 1976
    1976 Antibodies to human native and denatured collagens in synovial fluids of patients with rheumatoid arthritisAntioxidants.  6:209-212. 1976
    1976 Isolation and properties of the CNBr peptides of influenza viral membrane proteinFederation proceedings.  35. 1976
    1976 Quantitative Isolation of Mouse Thymus Leukemia Antigen, TLTissue Antigens.  7:158-164. 1976
    1975 Subfragments of papain solubilized TL antigenJournal of Immunology.  115:1013-1017. 1975
    1975 Purification of Murine Thymus Leukemia Antigen (TL). A Quantitative Assessment of Limited ProteolysisBiomarker Insights.  14:4792-4796. 1975
    1975 C1 fixation and classical complement pathway activation by a fragment of the Cμ4 domain of IgMJournal of Experimental Medicine.  142:1322-1326. 1975
    1975 The primary structure of J chain: sequence analyses of the major proteolytic fragmentsFederation proceedings.  34:4160. 1975
    1973 Rheumatoid arthritis: an immune complex disease?Geriatrics -Minnesota-.  28:84-91. 1973
    1973 Characterization of a teleost immunoglobulin: The immune macroglobulin from the channel catfish, Ictalurus punctatusMolecular Diagnosis.  46. 1973
    1973 Isolation and characterization of the glycopeptides from a human immunoglobulin M.Journal of Immunology.  110:840-847. 1973
    1973 Isolation of f(c)5μ and fabμ fragments of human igmEuropean Journal of Immunology.  3:415-419. 1973
    1972 The carbohydrate composition of immunoglobulins from diverse species of vertebrates.Journal of Immunology.  109:371-381. 1972
    1972 Purification and Characterization of Two Classes of Immunoglobulins from the Marine Toad, Bufo marinusBiomarker Insights.  11:2751-2759. 1972
    1972 Studies of the component chains of human IgM by citraconylationHybridoma and Hybridomics.  263:339-350. 1972
    1971 Isolation and characterization of the immune macroglobulin from the paddlefish, Polyodon spathula.Journal of Biological Chemistry.  246:6760-6769. 1971
    1971 Degradation of human IgM by pepsin: characterization of a high molecular weight fragment.Journal of Immunology.  107:870-880. 1971
    1971 Isolation and physico-chemical characterization of the "IgM-like" immunologlobulin from the stingray Dasyatis americana.Journal of Immunology.  107:782-793. 1971
    1971 The carbohydrate composition of immunoglobulins GCirculation Research.  237:442-449. 1971
    1971 Phylogeny of Immunoglobulins. Characterization of a 14S Immunoglobuim from the Gar, Lepisosteus osseusBiomarker Insights.  10:2028-2036. 1971
    1971 Oxidative sulfitolysis of human IgM.Journal of Immunology.  106:1136-1138. 1971
    1971 Tetrameric immune macroglobulins in three orders of bony fishes.Proceedings of the National Academy of Sciences.  68:107-111. 1971
    1970 Biological sciences: N-Terminal sequences of immunoglobulin heavy and light chains from three species of lower vertebratesNature.  228:991-992. 1970
    1970 Studies of maleylated chains of human IgM.Journal of Immunology.  105:846-855. 1970
    1970 Antibodies to ribosomal ribonucleic acid (rRNA) in patients with systemic lupus erythematosus (SLE).Immunology.  19:439-442. 1970
    1970 Release of Fab- and Fc-like fragments from human IgM by reductive cleavage.Journal of Immunology.  104:518-521. 1970
    1970 Antibodies to Homologous RNA in the Rabbit Following Stimulation By Exogenous RNA (34922)Proceedings of the Society for Experimental Biology and Medicine.  134:968-970. 1970
    1969 Physical and chemical characterization of an oyster hemagglutinin.Journal of Biological Chemistry.  244:4128-4135. 1969
    1969 Immunological capabilities of the oyster Crassostrea virginicaEnfermería Global.  29:149-160. 1969
    1969 Management of rheumatoid arthritisSouthern Medical Journal.  62:307-314. 1969
    1969 Possible Usefulness of Azathioprine (Imuran) In Severe Rheumatoid ArthritisThe Journal of clinical pharmacology and the journal of new drugs.  9:251-258. 1969
    1969 Studies on the structural variation of the H chain of immunoglobulin M(IgM)Heliyon.  131:551-560. 1969
    1968 The Amino-Terminal Sequence of the Heavy Chain of Human Immunoglobulin MBiomarker Insights.  7:3340-3344. 1968
    1967 [36] Paper chromatography and electrophoresis; special procedure for peptide mapsMethods in Enzymology.  11:330-339. 1967
    1966 Concluding remarks: the regulation of hemoglobin and immunoglobulin synthesis.Journal of Cellular Physiology.  67. 1966
    1966 Concluding remarks: The regulation of hemoglobin and immunoglobulin synthesisJournal of Cellular Physiology.  67:207-215. 1966
    1965 The molecular basis of antibody formation: a paradox.Proceedings of the National Academy of Sciences.  54:864-869. 1965
    1964 The relationship of the three dimensional conformation of proteins to their antigenic specificityMedicine.  43:305-314. 1964
    1963 Studies on antigen conformation during antibody purification.Journal of Biological Chemistry.  238:1362-1366. 1963
    1962 Polarization of fluorescence as a measure of antigen-antibody interaction.Proceedings of the National Academy of Sciences.  48:1935-1942. 1962

    Book

    Year Title Altmetric
    2000 Cross-species comparison of in vivo reported gene expression after recombinant adeno-associated virus-mediated retinal transduction.  Ed. 316.  2000

    Chapter

    Year Title Altmetric
    2018 Liquid phase sequence analysis of proteinsipeptides.  49-71. 2018
    2016 Evaluation of ocular gene therapy in an italian patient affected by congenital leber amaurosis type 2 treated in both eyes.  533-539. 2016
    2013 Gene therapy and pharmacology 2013
    2012 Gene Therapy for Retinal Disease.  652-668. 2012
    2012 Gene delivery to the Retina: From mouse to man.  255-274. 2012
    2008 Progress and Prospects in Ocular Gene Therapy.  393-420. 2008
    2006 Gene therapy for retinal disease.  157-174. 2006

    Education And Training

  • Doctor of Medicine, Harvard University 1958
  • Full Name

  • J Bennett